Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IDT Australia Limited ( (AU:IDT) ) has provided an update.
IDT Australia director Mark Simari has increased his indirect shareholding in the company through entities Charkaroo Pty Ltd and Jodmar Pty Ltd, which collectively acquired 325,000 fully paid ordinary shares in on-market trades. The purchases, executed on 24 March 2026 at prices between $0.044 and $0.045 per share, lift his indirect holding to 1,412,912 shares while his 6,000,000 unlisted options remain unchanged, signaling a modest vote of confidence in the company without altering its capital structure.
The change in Simari’s interests did not involve any disposals of existing securities or any new contractual arrangements related to IDT Australia securities. The trades were conducted outside a closed period and therefore did not require prior written clearance, suggesting routine portfolio adjustment yet providing shareholders with additional transparency on director alignment with equity holders.
The most recent analyst rating on (AU:IDT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.
More about IDT Australia Limited
IDT Australia Limited is an Australian pharmaceutical manufacturer focused on producing and developing medicines, with its securities listed on the ASX. The company operates within the healthcare and life sciences industry, where director and insider share movements are closely monitored by investors and regulators as indicators of management confidence and alignment with shareholders.
Average Trading Volume: 194,312
Technical Sentiment Signal: Sell
Current Market Cap: A$18.51M
See more data about IDT stock on TipRanks’ Stock Analysis page.